Side population cells originated from human amnion and their uses

• US 20050089513A1
• Filed: 08/17/2004
• Published: 04/28/2005
• Est. Priority Date: 10/28/2003
• Status: Abandoned Application

• Current Assignee: SRL Incorporated (H.U. Group Holdings, Inc.), Norio Sakuragawa
• Original Assignee: SRL Incorporated (H.U. Group Holdings, Inc.), Norio Sakuragawa
• Inventors: Yokoyama, Yasunobu, Sakuragawa, Norio
• Application Number:
  US10/919,310
• Publication Number:
  US 20050089513A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2500/44 Thiols, e.g. mercaptoethanol
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

Cells which may be differentiated at least into nerve cells, which are useful for therapies of brain metabolic diseases, are disclosed. The cells are side population cell separated from human amniotic mesenchymal cell layer, in which expressions of Oct-4 gene, Sox-2 gene and Rex-1 gene are observed by RT-PCR, and which are vimentin-positive and CK19-positive in immunocytostaining.

Claims

1. A side population cell separated from human amniotic mesenchymal cell layer, in which expressions of Oct-4 gene, Sox-2 gene and Rex-I gene are observed by RT-PCR, and which is vimentin-positive and CK19-positive in immunocytostaining.

2. The side population cell according to claim 1, which is major histocompatibility antigen class II-negative and major histocompatibility antigen class I-positive.

3. An assemblage of side population cells separated from human amniotic mesenchymal cell layer, comprising cells which are major histocompatibility antigen class II-negative and major histocompatibility antigen class I-negative, and cells which are major histocompatibility antigen class II-negative and major histocompatibility antigen class I-positive.

4. A method for transplantation comprising transplanting side population cells separated from human amniotic mesenchymal cell layer.

5. The method according to claim 4, wherein said cells are transplanted to human brain.

6. A method for therapy of a brain metabolic disease, comprising administering an effective amount of side population cells separated from human amniotic mesenchymal cell layer.

7. A method for therapy of β

-galactosidase-deficiency and/or β

-glucosidase-deficiency, comprising administering an effective amount of side population cells separated from human amniotic mesenchymal cell layer.